NID2 and neoplasm: Through organotypic models, advanced intravital imaging, and coinjection in vivo experiments using NID2-depleted CAFs, we have shown that NID2 contributes to tumor fibrosis and metastasis, while in the context of gemcitabine/Abraxane chemotherapy, NID2 can alter tumor vasculature and improve response the therapy.